Risk-based lung cancer screening in heavy smokers: a benefit–harm and cost-effectiveness modeling study

Liu, Yin; Xu, Huifang; Lv, Lihong; Wang, Xiaoyang; Kang, Ruihua; Guo, Xiaoli; Wang, Hong; Zheng, Liyang; Liu, Hongwei; Guo, Lanwei; Chen, Qiong; Liu, Shuzheng; Qiao, Youlin; Zhang, Shaokai

doi:10.1186/s12916-024-03292-4

Table 3 Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs

From: Risk-based lung cancer screening in heavy smokers: a benefit–harm and cost-effectiveness modeling study

Strategy	Costs per 100,000 people (CNY, thousand)	Incremental cost per 100,000 people (CNY, thousand)		QALYs per 100,000 people	Incremental QALYs per 100,000 people		ICER (CNY/QALY)		iNMB
Strategy	Costs per 100,000 people (CNY, thousand)	Vs the status quo strategy	Vs the strategy preceding it on the efficiency frontier	QALYs per 100,000 people	Vs the status quo strategy	Vs the strategy preceding it on the efficiency frontier	Vs the status quo strategy	Vs the strategy preceding it on the efficiency frontier	iNMB
No screening	845,168	− 434,090	NA	1,150,366	− 3235	NA	Dominated	NA	− 3518
H1-MHnone-LMnone-Lnone	924,335	− 354,923	79,167	1,151,147	− 2453	781	Dominated	101,309	− 2411
H1-MHone-off-LMone-off-Lnone	947,457	− 331,801	102,289	1,151,200	− 2400	834	Dominated	122,594	− 2513
H1-MHone-off-LMone-off-Lone-off	958,602	− 320,655	113,434	1,151,202	− 2398	837	Dominated	135,567	− 2619
H1-MHone-off-LMnone-Lnone	937,823	− 341,434	92,656	1,151,247	− 2354	881	Dominated	105,176	− 2304
H1-MH3-LMone-off-Lnone	999,095	− 280,162	153,928	1,152,081	− 1520	1715	Dominated	89,762	− 891
H1-MH3-LMone-off-Lone-off	1,010,241	− 269,017	165,073	1,152,083	− 1518	1717	Dominated	96,129	− 997
H1-MH3-LMnone-Lnone^a	989,462	− 289,795	144,295	1,152,127	− 1473	1761	Dominated	81,919	− 681
H1-MH2-LM3-Lnone	1,041,867	− 237,391	52,405	1,152,229	− 1372	101	Dominated	517,113	− 959
H1-MH2-LMone-off-Lnone	1,018,091	− 261,166	28,629	1,152,258	− 1343	131	Dominated	218,734	− 650
H1-MH2-LMone-off-Lone-off	1,029,237	− 250,021	39,774	1,152,260	− 1340	133	Dominated	298,492	− 755
H1-MH1-LM1-Lnone	1,123,224	− 156,033	133,762	1,152,277	− 1323	150	Dominated	891,217	− 1654
H1-MH2-LMnone-Lnone^a	1,008,458	− 270,799	18,996	1,152,305	− 1296	177	Dominated	107,036	− 440
H1-MH1-LMone-off-Lnone	1,047,048	− 232,210	38,590	1,152,354	− 1247	49	Dominated	781,869	− 706
H1-MH1-LMone-off-Lone-off	1,058,193	− 221,064	49,735	1,152,356	− 1244	52	Dominated	961,581	− 812
H1-MH1-LM2-Lnone	1,090,559	− 188,698	82,101	1,152,357	− 1243	53	Dominated	1,553,900	− 1133
H1-MH1-LMnone-Lnone	1,037,415	− 241,843	28,957	1,152,401	− 1200	96	Dominated	301,814	− 497
H1-MH3-LM3-Lnone	1,039,447	− 239,810	30,989	1,152,411	− 1190	106	Dominated	291,936	− 492
H1-MH3-LM3-Lone-off	1,050,593	− 228,665	42,135	1,152,413	− 1187	109	Dominated	388,277	− 598
H1-MH2-LM3-Lone-off	1,069,589	− 209,669	61,131	1,152,591	− 1010	286	Dominated	213,752	− 357
H1-MH2-LM2-Lnone	1,078,179	− 201,079	69,721	1,152,621	− 979	317	Dominated	220,186	− 368
H1-MH2-LM2-Lone-off	1,089,324	− 189,933	80,866	1,152,624	− 977	319	Dominated	253,490	− 474
H1-MH1-LM1-Lone-off	1,150,946	− 128,312	142,488	1,152,639	− 961	335	Dominated	425,672	− 1052
H1-MH1-LM3-Lnone	1,087,400	− 191,858	78,942	1,152,684	− 916	380	Dominated	207,980	− 308
H1-MH1-LM3-Lone-off	1,098,545	− 180,712	90,087	1,152,687	− 914	382	Dominated	235,874	− 413
H1-MH1-LM2-Lone-off	1,118,281	− 160,977	109,823	1,152,720	− 881	415	Dominated	264,663	− 530
H1-MH3-LM3-L3^a	1,114,292	− 164,966	105,834	1,153,247	− 354	942	Dominant	112,300	791
H1-MH2-LM3-L3^a	1,133,288	− 145,970	18,996	1,153,425	− 176	177	Dominant	107,036	1032
H1-MH2-LM2-L3	1,153,023	− 126,234	38,731	1,153,458	− 143	33	Dominant	1,172,851	915
H1-MH1-LM1-L3	1,214,645	− 64,613	100,353	1,153,473	− 127	49	Dominant	2,058,604	337
H1-MH1-LM3-L3	1,162,244	− 117,013	47,952	1,153,520	− 80	96	Dominant	499,807	975
H1-MH1-LM2-L3	1,181,980	− 97,277	67,688	1,153,554	− 47	129	Dominant	524,855	858
H1-MH2-LM2-L2^a	1,177,849	− 101,409	63,557	1,153,596	− 5	171	Dominant	371,625	1002
H1-MH1-LM1-L1 (status quo strategy)	1,279,258	NA	101,409	1,153,601	NA	5	NA	20,062,309	NA
H1-MH1-LM1-L2	1,239,470	− 39,787	61,622	1,153,611	11	16	Cost-saving	3,918,770	424
H1-MH1-LM2-L2^a	1,206,805	− 72,452	28,957	1,153,692	91	96	Cost-saving	301,814	945

QALY quality-adjusted life year, ICER the incremental cost-effectiveness ratio, iNMB incremental net monetary benefit
^aThese strategies comprised the cost-effectiveness efficiency frontier

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com

BMC Medicine

Contact us